Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

154.58
-0.3500-0.23%
Post-market: 153.90-0.6801-0.44%19:57 EDT
Volume:8.64M
Turnover:1.33B
Market Cap:371.93B
PE:17.20
High:154.90
Open:154.32
Low:152.45
Close:154.93
Loading ...

Shares of Drugmakers Down After Trump Threatens Tariffs on Sector

THOMSON REUTERS
·
09 Apr

Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma

MT Newswires Live
·
09 Apr

Stock Track | Johnson & Johnson Plunges 5.19% Pre-market on Trump's Pharmaceutical Tariff Threat

Stock Track
·
09 Apr

Johnson & Johnson’s Darzalex with Halozyme’s Enhanze granted EU approval

TIPRANKS
·
09 Apr

Morgan Stanley Remains a Hold on Johnson & Johnson (JNJ)

TIPRANKS
·
09 Apr

Johnson & Johnson Raised to Buy From Neutral by Goldman Sachs

Dow Jones
·
09 Apr

Morgan Stanley Adjusts PT on Johnson & Johnson to $164 From $163, Maintains Equalweight Rating

MT Newswires Live
·
09 Apr

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

Johnson & Johnson (JNJ): Among Defensive Stocks Billionaire Ken Fisher is Betting On

Insider Monkey
·
09 Apr

Johnson & Johnson (JNJ) Stock Moves -0.52%: What You Should Know

Zacks
·
09 Apr

Johnson & Johnson assumed at Buy from Neutral at Goldman Sachs

TIPRANKS
·
09 Apr

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

Benzinga
·
09 Apr

Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie

GuruFocus
·
09 Apr

Top Calls on Wall Street: Nvidia, Tesla, Apple, AMD, Coinbase, Affirm, Wells Fargo, and More

Tiger Newspress
·
08 Apr

Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
08 Apr

Johnson & Johnson announces results from Vivacity-MG3 study

TIPRANKS
·
08 Apr

Johnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis

MT Newswires Live
·
08 Apr

Johnson & Johnson assumed with a Buy at Goldman Sachs

TIPRANKS
·
08 Apr

J&J - up to 128 Weeks & 180 Patient Years of Follow-up in Open-Label Extension(a) Confirm Safety Profile Consistent With Phase 3 Vivacity-Mg3 Study

THOMSON REUTERS
·
08 Apr

J&J- Results Show 18 Months of Sustained Reduction in Immunoglobulin G Antibodies & Sustained Improvement in Gmg Symptoms

THOMSON REUTERS
·
08 Apr